Background and Aims: To evaluate the possible modifying e ect of the peroxisome-proliferator-activated receptor gene (PPARG) polymorphism on the e ciency of pioglitazone (Actos®) treatment with regard to glycaemic control in both men and women with type 2 diabetes (T2D).
Results: There were 248 patients with the Pro12Pro genotype and 78 with the Pro12Ala genotype, no di erence between females and males (p=0.78). HbA1c decreased signicantly between visits, in both females and males (p<0.001).
Materials and Methods: A total of 326 patients with T2D, in a normal clinical practice setting, were treated with pioglitazone at the dose of 15–30 mg/day for 26 weeks, added to existing oral anti-diabetic medication. All were genotyped for the Pro12Ala variant of the PPARG. Insulin resistance and -cell function was calculated using HOMA model.
Results: Tere were 248 patients with the Pro12Pro genotype and 78 with the Pro12Ala genotype, no difference between females and males (p=0.78). HbA1c decreased signicantly between visits, in both females and males (p<0.001).The difference between visits across gender depended on genotype, with a signicantly larger decrease in the Pro12Pro genotype (p=0.026). Insulin resistance fell signicantly across gender and genotype between visits (p< 0.001), but the change across gender was signi cantly greater for the Pro12Pro genotype (p=0.034), compared to baseline.
Conclusion: In patients with T2D, the effects of pioglitazone treatment on metabolic control and insulin sensitivity may vary dependent on the wild type Pro12Pro variant of the PPAR gene. erefore, assessment of the Pro12Pro variant may in future prove to have clinical signi cance in the identi cation of patients with T2D who will bene t from pioglitazone treatment. Supported by Eli Lilly and Company
2007. Vol. 50, no S1, S357-S358 p.